Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01468987
Registration number
NCT01468987
Ethics application status
Date submitted
8/11/2011
Date registered
10/11/2011
Date last updated
17/04/2018
Titles & IDs
Public title
A Study in Participants With Type 2 Diabetes Mellitus
Query!
Scientific title
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin With Insulin Lispro: a Double-Blind, Randomized, 26-week Study - The IMAGINE 4 Study
Query!
Secondary ID [1]
0
0
I2R-MC-BIAM
Query!
Secondary ID [2]
0
0
12145
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMAGINE 4
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - LY2605541
Treatment: Drugs - Insulin Glargine
Treatment: Drugs - Insulin Lispro
Active Comparator: Insulin Glargine + Insulin Lispro - Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.
Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks.
Experimental: LY2605541 + Insulin Lispro - Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.
Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks.
Treatment: Drugs: LY2605541
Treatment: Drugs: Insulin Glargine
Treatment: Drugs: Insulin Lispro
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks
Query!
Assessment method [1]
0
0
HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for stratification factors (country, low-density lipoprotein cholesterol [LDL-C, <100 milligrams per deciliter (mg/dL) and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), visit, treatment, visit-by-treatment interaction, and baseline HbA1c.
Query!
Timepoint [1]
0
0
Baseline, 26 weeks
Query!
Secondary outcome [1]
0
0
Total Hypoglycemia Rates (Adjusted for 30 Days)
Query!
Assessment method [1]
0
0
Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of =70 mg/dL (3.9 millimoles per liter [mmol/L]). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log [exposure in days/30] as an offset variable). Group Mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.
Query!
Timepoint [1]
0
0
Baseline through 26 weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Total Hypoglycemia Episodes
Query!
Assessment method [2]
0
0
Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of =70 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [2]
0
0
Baseline through 26 weeks
Query!
Secondary outcome [3]
0
0
Nocturnal Hypoglycemia Rates (Adjusted for 30 Days)
Query!
Assessment method [3]
0
0
Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log [exposure in days/30] as an offset variable). Group Mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.
Query!
Timepoint [3]
0
0
Baseline through 26 weeks
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Nocturnal Hypoglycemia Episodes
Query!
Assessment method [4]
0
0
Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia and/or a BG concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [4]
0
0
Baseline through 26 weeks
Query!
Secondary outcome [5]
0
0
Body Weight Change From Baseline to 26 Weeks
Query!
Assessment method [5]
0
0
LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), treatment, visit, treatment-by-visit interaction, and baseline body weight as fixed effects, and participant as a random effect.
Query!
Timepoint [5]
0
0
Baseline, 26 weeks
Query!
Secondary outcome [6]
0
0
Self-Monitored Blood Glucose (SMBG) 9-point Profiles at 26 Weeks
Query!
Assessment method [6]
0
0
9-point SMBG profiles were obtained over 2 nonconsecutive days within the week prior to Weeks 0, 4, 12, and 26. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), visit, treatment, visit-by-treatment interaction, and baseline BG values.
Query!
Timepoint [6]
0
0
26 weeks
Query!
Secondary outcome [7]
0
0
Percentage of Participants With HbA1c <7.0% and =6.5% at 26 Weeks
Query!
Assessment method [7]
0
0
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [7]
0
0
up to 26 weeks
Query!
Secondary outcome [8]
0
0
Percentage of Participants With HbA1c <7.0% Without Nocturnal Hypoglycemia at 26 Weeks
Query!
Assessment method [8]
0
0
Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c <7.0% without nocturnal hypoglycemia by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [8]
0
0
up to 26 weeks
Query!
Secondary outcome [9]
0
0
Basal, Bolus, and Total Insulin Dose by Weight at 26 Weeks
Query!
Assessment method [9]
0
0
Basal insulin dose, short-acting bolus insulin dose (each meal and overall), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using a constrained Longitudinal Data Analysis (cLDA) model adjusting for indicator variables of each treatment group at each post-baseline visit and stratification variables (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL and =100 mg/dL], and baseline number of insulin injections [1, 2, or =3]).
Query!
Timepoint [9]
0
0
26 weeks
Query!
Secondary outcome [10]
0
0
Fasting Serum Glucose (FSG) From Laboratory at 26 Weeks
Query!
Assessment method [10]
0
0
LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), treatment, visit, treatment-by-visit interaction, and baseline FSG.
Query!
Timepoint [10]
0
0
26 weeks
Query!
Secondary outcome [11]
0
0
Fasting Blood Glucose (FBG) (by SMBG) Intra-participant Variability at 26 Weeks
Query!
Assessment method [11]
0
0
FBG was measured by self-monitored blood glucose (SMBG). Between-day glucose variability is measured by the standard deviation of FBG. LS means were calculated using MMRM adjusting for the stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), treatment, visit, treatment-by-visit interaction, and baseline FBG variability.
Query!
Timepoint [11]
0
0
26 weeks
Query!
Secondary outcome [12]
0
0
0300-hour Blood Glucose to FBG Excursion at 26 Weeks
Query!
Assessment method [12]
0
0
Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only SMBG profiles with both 0300 hours and the next day pre-morning measurements are included for the calculation of such excursion). LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), treatment, visit, treatment-by-visit interaction, and baseline excursion.
Query!
Timepoint [12]
0
0
26 weeks
Query!
Secondary outcome [13]
0
0
HbA1c at 26 Weeks
Query!
Assessment method [13]
0
0
HbA1c is a test that measures a participant's average blood glucose level over the past 2 to 3 months. LS means were calculated using MMRM adjusting for stratification factors (country, LDL-C [<100 mg/dL and =100 mg/dL], and number of insulin injections at baseline [1, 2, or =3]), treatment, visit, treatment, visit-by-treatment interaction, and baseline HbA1c.
Query!
Timepoint [13]
0
0
26 weeks
Query!
Secondary outcome [14]
0
0
Lipid Profile at 26 Weeks
Query!
Assessment method [14]
0
0
Concentrations of cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C, and triglycerides are summarized. LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, LDL-C [<100 mg/dL and =100 mg/dL], except for the LDL-C outcome variable], number of insulin injections at baseline [1, 2, or =3]), visit, treatment, visit-by-treatment interaction, and baseline value of corresponding lipid outcome variable.
Query!
Timepoint [14]
0
0
26 weeks
Query!
Secondary outcome [15]
0
0
Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks
Query!
Assessment method [15]
0
0
The number of participants with a treatment-emergent anti-LY2605541 antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable, or from detectable to the value with at least 130% relative increase from baseline.
Query!
Timepoint [15]
0
0
Baseline through 26 weeks
Query!
Secondary outcome [16]
0
0
Insulin Treatment Satisfaction Questionnaire (ITSQ) at 26 Weeks
Query!
Assessment method [16]
0
0
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an analysis of covariance (ANCOVA) model with treatment and stratification factors (baseline HbA1c [=8.5% and >8.5%], country, and baseline number of insulin injections [1, 2, or =3]) as fixed effects and baseline value of the ITSQ scores as a covariate.
Query!
Timepoint [16]
0
0
up to 26 weeks
Query!
Secondary outcome [17]
0
0
Low Blood Sugar Survey (LBSS) at 26 Weeks
Query!
Assessment method [17]
0
0
LBSS (also referenced as Hypoglycemia Fear Survey - II [HFS-II]) is a 33-item questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM including stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline number of insulin injections [1, 2, or =3]), visit, treatment, visit-by-treatment interaction, and baseline LBSS score.
Query!
Timepoint [17]
0
0
26 weeks
Query!
Secondary outcome [18]
0
0
EuroQoL-5D (EQ-5D) at 26 Weeks
Query!
Assessment method [18]
0
0
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using ANCOVA adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, and baseline number of insulin injections [1, 2, or = 3]), and baseline EQ-5D score.
Query!
Timepoint [18]
0
0
up to 26 weeks
Query!
Secondary outcome [19]
0
0
Rapid Assessment of Physical Activity (RAPA) at 26 Weeks
Query!
Assessment method [19]
0
0
The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activities, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility activity, either strength or flexibility activity (not both), both strength and flexibility activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [19]
0
0
up to 26 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Have type 2 diabetes mellitus based on the World Health Organization (WHO)
classification
- Had diabetes =1 year
- Have a hemoglobin A1c (HbA1c) value =7.0% and <12.0% at screening
- Have a body mass index (BMI) =45.0 kilograms per square meter (kg/m^2)
- Participants on any glucose lowering regimen that contains at least 1 daily insulin
injection
- This inclusion criterion applies ONLY to women of childbearing potential
- Are not breastfeeding
- Test negative for pregnancy at screening and randomization
- Do not intend to become pregnant during the study
- Have practiced a reliable method of birth control for at least 6 weeks prior to
screening
- Agree to continue to use a reliable method of birth control during the study, as
determined by the investigator (and for 2 weeks following the last dose of study
drug)
- Have access to a method of communication with the site
- Have refrigeration in the home
- Capable of, and willing to do the following: adhere to a multiple daily injection
regimen, inject insulin with a covered vial and syringe and prefilled pen, attend some
appointments in the fasting state, and perform self blood glucose monitoring and
record keeping as required by this protocol, as determined by the investigator.
Caregiver may be responsible for all of the above
- Have given written informed consent to participate in this study in accordance with
local regulations
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Continuous subcutaneous insulin infusion therapy prior to screening
- Are using twice daily insulin glargine prior to screening
- Excessive insulin resistance defined as having received a daily dose of insulin =2.0
units per kilogram (units/kg) at the time of pre-randomization
- Glucagon-like peptide-1 (GLP-1) receptor agonist (eg, exenatide, exenatide once
weekly, or liraglutide), thiazolidinedione (rosiglitazone, pioglitazone), or
pramlintide, used concurrently or within 90 days prior to screening
- Are using niacin preparations as a lipid-lowering medication and/or bile acid
sequestrants within 90 days prior to screening; or, are using lipid-lowering
medication at a dose that has not been stable for =90 days prior to screening
- Have fasting hypertriglyceridemia (defined as >4.5 millimoles per liter [mmol/L], >400
milligrams per deciliter [mg/dL]) at screening
- Are currently taking, or have taken within the 90 days preceding screening,
prescription or over-the-counter medications for weight loss
- Have had any episode of severe hypoglycemia (defined as requiring assistance due to
neurologically disabling hypoglycemia) within 6 months prior to entry into the study
- Have had 2 or more emergency room visits or hospitalizations due to poor glucose
control within the 6 months prior to screening
- Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma requiring
hospitalization within 6 months prior to screening
- Have cardiac disease with functional status that is New York Heart Association Class
III or IV (per New York Heart Association Cardiac Disease Classification)
- Are currently receiving renal dialysis or have a serum creatinine =2.0 mg/dL, except
for participants taking metformin who will be required to follow local labeling
restrictions regarding metformin use and serum creatinine
- Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic
fatty liver disease [NAFLD], acute or chronic hepatitis, non-alcoholic steatohepatitis
[NASH], or elevated liver enzyme measurements as indicated below:
- total bilirubin =2X the upper limit of normal (ULN) as defined by the central
laboratory, or
- alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >2.5X
ULN as defined by the central laboratory, or
- aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT)
>2.5X ULN as defined by the central laboratory
- Have active or untreated malignancy, have been in remission from clinically
significant malignancy (other than basal cell or squamous cell skin cancer) for less
than 5 years, or are at increased risk for developing cancer or a recurrence of cancer
in the opinion of the investigator
- Have known or develop hypersensitivity or allergy to any of the study insulins or
their excipients
- Have had a blood transfusion or severe blood loss within 3 months prior to screening
or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other
traits of hemoglobin abnormalities known to interfere with the HbA1c measurement
- Receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid
therapy (excluding topical, intraocular, intranasal, and inhaled preparations) or have
received such therapy within 8 weeks immediately before screening with the exception
of replacement therapy for adrenal insufficiency
- Diagnosed clinically significant diabetic autonomic neuropathy, in the opinion of the
investigator
- Have had an organ transplant
- Have any other condition (including known drug or alcohol abuse or psychiatric
disorder including eating disorder) that precludes the participant from following and
completing the protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1369
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Camperdown
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - St Leonards
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daw Park
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - East Ringwood
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Geelong
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville
Query!
Recruitment hospital [7]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [4]
0
0
3135 - East Ringwood
Query!
Recruitment postcode(s) [5]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [7]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Montana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Hampshire
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Jersey
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Washington
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Graz
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Vienna
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Aparecida De Goiania
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Brasilia
Query!
Country [35]
0
0
Croatia
Query!
State/province [35]
0
0
Cakovec
Query!
Country [36]
0
0
Croatia
Query!
State/province [36]
0
0
Osijek
Query!
Country [37]
0
0
Croatia
Query!
State/province [37]
0
0
Rijeka
Query!
Country [38]
0
0
Croatia
Query!
State/province [38]
0
0
Slavonski Brod
Query!
Country [39]
0
0
Croatia
Query!
State/province [39]
0
0
Varazdin
Query!
Country [40]
0
0
Croatia
Query!
State/province [40]
0
0
Zagreb
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Holesov
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Hranice I-Mesto
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Krnov
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Pardubice
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Prague
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Esbjerg
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Hillerod
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Kobenhavn
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Berlin
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Burghausen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Eisenach
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Essen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Falkensee
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Mainz
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Mayen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Münster
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Neuwied
Query!
Country [58]
0
0
Greece
Query!
State/province [58]
0
0
Ampelokipoi
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Athens
Query!
Country [60]
0
0
Greece
Query!
State/province [60]
0
0
Nikaias - Piraeus
Query!
Country [61]
0
0
Greece
Query!
State/province [61]
0
0
Thessaloniki
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Bekescsaba
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Budapest
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Gyula
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Veszprem
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Zalaegerszeg
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Beer Sheva
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Holon
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Jerusalem
Query!
Country [70]
0
0
Israel
Query!
State/province [70]
0
0
Nahariya
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Safed
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Tel Hashomer
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Bergamo
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Bologna
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Olbia
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Pavia
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Rozzano
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Kanagawa
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Kumamoto
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Tokyo
Query!
Country [81]
0
0
Lithuania
Query!
State/province [81]
0
0
Kaunas
Query!
Country [82]
0
0
Lithuania
Query!
State/province [82]
0
0
Klaipeda
Query!
Country [83]
0
0
Mexico
Query!
State/province [83]
0
0
Monterrey
Query!
Country [84]
0
0
Mexico
Query!
State/province [84]
0
0
Queretaro
Query!
Country [85]
0
0
Mexico
Query!
State/province [85]
0
0
Tampico
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Dordrecht
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Groningen
Query!
Country [88]
0
0
Netherlands
Query!
State/province [88]
0
0
Heerlen
Query!
Country [89]
0
0
Netherlands
Query!
State/province [89]
0
0
Hoogeveen
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Leiden
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Krakow
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lublin
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Sopot
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Szczecin
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Wroclaw
Query!
Country [96]
0
0
Puerto Rico
Query!
State/province [96]
0
0
Caguas
Query!
Country [97]
0
0
Puerto Rico
Query!
State/province [97]
0
0
Las Lomas
Query!
Country [98]
0
0
Puerto Rico
Query!
State/province [98]
0
0
Manati
Query!
Country [99]
0
0
Puerto Rico
Query!
State/province [99]
0
0
San Juan
Query!
Country [100]
0
0
Puerto Rico
Query!
State/province [100]
0
0
Yabucoa
Query!
Country [101]
0
0
Romania
Query!
State/province [101]
0
0
Brasov
Query!
Country [102]
0
0
Romania
Query!
State/province [102]
0
0
Cluj
Query!
Country [103]
0
0
Romania
Query!
State/province [103]
0
0
Oradea
Query!
Country [104]
0
0
Romania
Query!
State/province [104]
0
0
Ploiesti
Query!
Country [105]
0
0
Romania
Query!
State/province [105]
0
0
Satu Mare
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Arkhangelsk
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Moscow
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Rostov-On-Don
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Saint Petersburg
Query!
Country [110]
0
0
Slovakia
Query!
State/province [110]
0
0
Dolny Kubin
Query!
Country [111]
0
0
Slovakia
Query!
State/province [111]
0
0
Kosice
Query!
Country [112]
0
0
Slovakia
Query!
State/province [112]
0
0
Lubochna
Query!
Country [113]
0
0
Slovakia
Query!
State/province [113]
0
0
Roznava
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Barcelona
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Málaga
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Sabadell
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Sevilla
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Seville
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Chiayi City
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Sindian City
Query!
Country [121]
0
0
Taiwan
Query!
State/province [121]
0
0
Taichung
Query!
Country [122]
0
0
Taiwan
Query!
State/province [122]
0
0
Yong Kung City
Query!
Country [123]
0
0
Turkey
Query!
State/province [123]
0
0
Ankara
Query!
Country [124]
0
0
Turkey
Query!
State/province [124]
0
0
Diyarbakir
Query!
Country [125]
0
0
Turkey
Query!
State/province [125]
0
0
Istanbul
Query!
Country [126]
0
0
Turkey
Query!
State/province [126]
0
0
Kayseri
Query!
Country [127]
0
0
Turkey
Query!
State/province [127]
0
0
Kutahya
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Cleveland
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Leicestershire
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Scotland
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is:
- To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after
26 weeks of treatment.
- To compare the rate of night time hypoglycemia (low blood glucose) on LY2605541 with
insulin glargine during 26 weeks of treatment.
- To compare the number of participants on LY2605541 reaching blood glucose targets
without hypoglycemia episodes at night to those taking insulin glargine after 26 weeks
of treatment.
- To compare the rate of hypoglycemia over a 24-hour period on LY2605541 with insulin
glargine during 26 weeks of treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01468987
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01468987
Download to PDF